Research Insight
Novartis, Intellia and Caribou to develop new medicines and drug discovery tools
Swiss drug-maker Novartis has entered collaboration and licensing agreements with Intellia Therapeutics to develop new medicines using CRISPR genome editing technology and Caribou Biosciences...
Press Releases
Janssen Healthcare Innovation two-time finalistsat eyeforpharma Barcelona Awards
Janssen Healthcare Innovation’s Care4Today programme is set to take two of the highest honours at the 2015 eyeforpharma Barcelona Awards as the shortlist was...
Press Releases
Apps & Digital Resources vie for top honour at eyeforpharma Barcelona Awards
Two thirds of the finalists for the ‘Most Valuable Patient Initiative’ in the 2015 eyeforpharma Barcelona Awards have used interactive digital resources or mobile...
Press Releases
TxCell receives EU Orphan Drug Designation for Col-Treg in the treatment of non-infectious uveitis
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic...
Press Releases
CARLINA Technologies signs a partnership agreement with Atlangram to develop controlled-release forms of antibiotics targeting osteoarticular diseases
Angers, France, December 16, 2014 - CARLINA Technologies, a biotechnology company specializing in the development of nanomedicines, today announces the signing of a partnership...
News
Mylan and Gilead partner for TAF-based HIV treatments in developing markets
Mylan Laboratories has signed an agreement with Gilead Sciences to increase access to Tenofovir Alafenamide (TAF) based HIV treatments in developing countries. ...
News
AstraZeneca (AZ) and Eli Lilly have started AMARANTH, a phase II/III study investigating a potential treatment for early Alzheimer’s disease.
The trial will examine oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293, also known as LY3314814, which reduced levels of amyloid-beta in the cerebro-spinal...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read